Volume 8, Supplement 4 (Oct 2017)

A rapidly emerging concept that holds the promise of altering the natural history and subsequently outcomes for cancer patients is that of precision—or personalized—medicine. There is an immediate and growing need to alert advanced practitioners about the role molecular profiling has in the treatment of non–small cell lung cancer, from a primarily prognostic role to one that can also provide predictive guidance regarding the choice of a specific therapy.